Abstract
The inhibition of antigen-induced bronchospasm by lodoxamide ethyl, a new drug with properties similar to those of cromolyn sodium, was studied in 13 asthmatic patients. Single doses were administered orally at weekly intervals in a double-blind randomized fashion 30 min before an inhalation challenge of antigen. The drug provided significant protection to immediate antigen-induced bronchospasm compared with placebo as measured by the antigen dose necessary to produce a drop of 20% or greater in the forced expiratory volume in 1 s.

This publication has 0 references indexed in Scilit: